Tien Liang Biotech Co

Tien Liang Biotech Co Net Margin

The Net Profit Margin of Tien Liang Biotech Co (4127.TWO) as of Nov 19, 2026 is -2.00 %. In the previous year, Net Profit Margin was 3.04 % — a change of -165.97% (lower).

Net Margin

-2.00 %

YoY

-165.97%

Last updated:

Net Profit Margin of Tien Liang Biotech Co is 2025 -2.00 % . Net Profit Margin of Tien Liang Biotech Co was 2024 3.04 % . It decreases by -165.97% lower compared to the previous year.

For Tien Liang Biotech Co, the net margin of -2.0% is down versus 8.2% a few years ago.

The Tien Liang Biotech Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-17.70 TWD
Jan 1, 2019
-10.73 TWD
Jan 1, 2020
-11.98 TWD
Jan 1, 2021
8.16 TWD
Jan 1, 2022
11.25 TWD
Jan 1, 2023
3.85 TWD
Jan 1, 2024
3.04 TWD
Jan 1, 2025
-2.00 TWD
The Tien Liang Biotech Co Net Margin history
YEARNet MarginYoY
-2.00 %-165.97%
3.04 %-21.23%
3.85 %-65.75%
11.25 %+37.96%
8.16 %-168.10%
-11.98 %+11.62%
-10.73 %-39.38%
-17.70 %-55.16%
-39.48 %+459.35%
-7.06 %-220.93%
5.84 %-19.91%
7.29 %+13,549.35%
0.05 %+27.66%
0.04 %-1,428.98%
-0.00-90.93%
-0.03 %-231.98%
0.03 %+35.64%
0.02 %+76.14%
0.01 %-86.90%
0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tien Liang Biotech Co Stock analysis

What does Tien Liang Biotech Co do? Tien Liang BioTech Co. Ltd. manufactures and sells Chinese herbal and western medicine, including active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicines. The company imports, wholesales, and retails western medicines domestically. Its products are distributed within the domestic market, targeting healthcare providers and consumers seeking traditional and modern pharmaceutical solutions. The firm's revenue streams come from the sale of manufactured medicines, APIs, biopharmaceuticals, and retail distribution of western medicines. Domestic market sales form the core of its business, with no mention of international distribution channels. The company serves both the traditional Chinese medicine segment and the modern pharmaceutical segment through its comprehensive product portfolio. Tien Liang BioTech operates within the pharmaceutical manufacturing and distribution sector, focusing on domestic sales of herbal, western, and biopharmaceutical products. Its business model integrates manufacturing, import, wholesale, and retail operations to serve the local healthcare market. Tien Liang Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tien Liang Biotech Co stock

Net Profit Margin of Tien Liang Biotech Co is -2.00 % in 2025.

Net Profit Margin of Tien Liang Biotech Co changed from 3.04 % to -2.00 %, representing a -165.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Tien Liang Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Tien Liang Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Tien Liang Biotech Co

All Key Metrics — Tien Liang Biotech Co